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Abstract 
Background & Aims 
Rifaximin- reduces the risk of recurrence of overt hepatic encephalopathy. However, there 
remain concerns regarding the financial cost of the drug. We aimed to study the impact of 
treatment with rifaximin- on healthcare resource utilisation using data from seven United 
Kingdom liver treatment centres. 
Methods 
All seven centres agreed a standardised data set and data characterising clinical, 
demographic and emergency hospital admissions were collected retrospectively for the 
time-periods three, six and 12 months before and following initiation of rifaximin-. 
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Admission rates and hospital length of stay before and during therapy were compared. 
Costs of admissions and drug acquisition were estimated using published sources. 
Multivariate analyses were carried out to assess the relative impact of various factors on 
hospital length of stay. 
Results 
Data were available from 326 patients. Following the commencement of rifaximin, the total 
hospital length of stay reduced by an estimated 31-53%, equating to a reduction in inpatient 
costs of between £4,858 and £6,607 per year. Taking into account drug costs of £3,379 for 
one year’s treatment with rifaximin-, there was an estimated annual mean saving of 
£1,480-£3,228 per patient. 
Conclusions 
Initiation of treatment with rifaximin- was associated with a marked reduction in the 
number of hospital admissions and hospital length of stay. These data suggest that 
treatment of patients with rifaximin- for hepatic encephalopathy was generally cost 
saving. 
Keywords: Hepatic encephalopathy; cirrhosis; rifaximin-; health economics 
 
Key points box 
 Rifaximin- has been shown to reduce the risk of recurrence of overt hepatic 
encephalopathy. However, there are concerns about the cost of the drug. 
 This study investigated the impact of treatment with rifaximin on hospital resource 
utilisation using real world data from 326 patients from seven UK liver centres. 
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 Following the commencement of rifaximin, there was an estimated 31-53% 
reduction in the total hospital length of stay, equating to a reduction in inpatient 
costs of between £4,858 and £6,607 per year. 
 Taking into account acquisition costs of rifaximin there was an estimated annual 
saving of around £1,500-£3,000 per patient. 
 
Introduction 
Hepatic encephalopathy (HE) is a neuropsychiatric complication of liver disease which 
results from liver dysfunction and/or portosystemic shunting (1). It spans a spectrum from 
covert HE—detectable only on neuropsychiatric testing—to overt HE, where clinical features 
such as confusion, impaired motor function, or decreased conscious level are manifest (2). 
Overt HE is estimated to affect 30%—40% of patients with cirrhosis at some time during the 
natural history of the disease (3), and it is associated with severely impaired health related 
quality of life (HRQOL) (4). HE has been recognised as carrying the highest mortality of all 
decompensation events (5). 
 
The pathophysiology of HE is not fully understood but it is thought that the accumulation of 
neurotoxins derived from bacteria in the gut, such as ammonia, play a part (6). For this 
reason, most treatments for HE target the removal of toxins within the gut, or modify gut 
microbiota. Non-absorbable disaccharides such as lactulose are recommended as the first 
line treatment for HE (7). Despite this, recurrence rates of overt HE are high and patient 
compliance can be poor.  
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The minimally absorbed (0.01%) antibiotic rifaximin- has been shown to reduce the risk of 
recurrence of HE in a high quality randomised controlled trial (RCT), with a hazard ratio of 
0.42 compared to placebo (8). In addition, this trial also showed an improvement in patient 
HRQOL (9). Moreover, a recent quality improvement initiative from the US showed that the 
treatment of HE with rifaximin- was associated with a reduction in 30 day readmission 
rates (odds ratio 0.39) (10). In the recent joint European Association for the Study of the 
Liver and American Association for the Study of Liver Disease HE guidelines, rifaximin has 
been recommended as second-line therapy, as an “add-on” to lactulose, after a second 
episode of overt HE (7). However, concerns have been raised about the cost-effectiveness of 
rifaximin (11, 12). 
 
There is emerging evidence to suggest that HE is associated with considerable financial 
burden to healthcare systems, partly due to high hospital admission rates (13, 14). Although 
the RCT of rifaximin showed a significant reduction in the rate of hospitalisation (hazard 
ratio 0.50) (8), there are understandable concerns about the reproducibility of such results 
outside the tightly controlled conditions of a RCT (15). Real world data, i.e. data derived 
from routine clinical practice, have the advantage of being potentially more generalisable 
than some of the results from RCTs. 
 
In this study, we compiled real world data from seven UK liver centres of patients with 
cirrhosis, treated with rifaximin- for HE. The primary aim was to compare the hospital 
resource utilisation for patients, before and after initiation of treatment with rifaximin. 
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Patients and methods 
Data collection 
A standardised data collection pro-forma was agreed by all participating centres. Adult 
patients commenced on rifaximin were identified retrospectively from the records of the 
pharmacy department at each specialist hospital. Patients who were treated for secondary 
prevention of overt HE on a background of chronic liver disease were included, while those 
with HE due to acute liver failure and patients who had an indication other than HE were 
excluded. Patient records were reviewed in 2014 and clinical and demographic data were 
recorded, along with the number and duration of emergency hospital admissions for the 
periods three, six and 12 months before and after rifaximin was commenced. Other relevant 
parameters which were collected included disease aetiology, abstinence status and length 
of abstinence in alcohol-related liver disease (ARLD), time since referral to a hepatologist or 
gastroenterologist, the presence of a transjugular intrahepatic portosystemic shunt (TIPSS), 
liver transplant status and mortality. In order to estimate disease severity, Model for End 
Stage Liver Disease (MELD) was calculated from serum bilirubin, creatinine and the 
international normalised ratio (INR) (16) at baseline, at three months and at the end of 
follow-up. Unlike the Child Pugh score, MELD is independent of the presence and severity of 
HE (17) and was therefore chosen for use in this study. 
Estimation of financial costs 
Table 1 shows the sources and values used to estimate costs. Inpatient costs were 
estimated in UK pounds sterling at 2013/14 prices from published NHS sources, at a mean 
cost of £513 per day for non-elective admissions with liver disease (18). Rifaximin drug costs 
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were calculated from the price published in the British National Formulary of £259 for 56 
550mg tablets (19), giving an annual drug treatment cost of £3,379 for the licensed HE dose 
of 550mg twice daily.  
Statistical analysis 
Whilst admissions data were non-normally distributed, the arithmetic mean value was used 
to compare these values, since we aimed to describe effects at the healthcare system level, 
rather than at the individual patient level. Mean admission rates and hospital length of stay 
(HLOS), before and during rifaximin exposure, were compared using paired samples t-tests. 
Otherwise, non-parametrically distributed data were compared using independent-samples 
Mann Whitney U tests or related-samples Wilcoxon signed rank test. The relationship 
between disease severity and response to rifaximin was explored using Pearson’s 
correlation between baseline MELD score and HLOS. Multivariate analysis was carried out 
using a negative binomial with log linking model where data were divided into two periods, 
one with and one without rifaximin. This allowed prescription of the drug to be included as a 
covariate. Patients who died, underwent liver transplantation or discontinued rifaximin 
were censored at the time of the event. All statistical analyses were carried out using SPSS 
version 21. 
Results 
Three hundred and twenty-six patients were identified across the seven centres. 169 
patients (51.8%) were prescribed rifaximin at a dose of 550mg twice daily, 151 (46.3%) were 
prescribed 400mg twice daily and six (1.8%) were taking another dose. Standard practice in 
all seven centres was for rifaximin to be prescribed to patients with HE refractory to 
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lactulose. The patient characteristics are summarised in Table 2. The most common liver 
disease aetiology was ARLD, affecting 199 patients (61%), 20 of whom also had another 
aetiology recorded (HCV, 12 patients; HBV, two; non-alcoholic fatty liver disease (NAFLD), 
four; haemochromatosis, two patients). Non-alcoholic steatohepatitis (NASH) and infection 
with hepatitis C virus (HCV) accounted for 15% and 13% of patients respectively. Ten 
patients had hepatocellular carcinoma. Mean age was 59 (S.D. 12) years and 225 (69%) were 
male. 282 patients (87%) were prescribed concurrent lactulose. In terms of disease severity, 
median MELD score was 13.7 (IQR 7.2) and Child Pugh grades were as follows: A, 29 (9%); B, 
153 (47%); and C, 142 (43%). 33 patients (10%) had a TIPSS placed prior to the initiation of 
rifaximin, 12 of which were placed within six months of rifaximin commencement. 
Of the patients with ARLD, 115 (58%) were abstinent from alcohol when rifaximin was 
initiated, 64 (32%) were actively drinking alcohol, and in 22 (11%) the alcohol status was 
unclear. Of the patients who abstained from alcohol, 69 (60%) had been abstinent for more 
one year, 24 (21%) for six to 12 months, whilst 20 (17%) had been abstinent for fewer than 
six months. 
The time interval between referral to a liver specialist and commencement of rifaximin was 
fewer than three months in 37 patients (11%), three to six months in 24 (7%), six months to 
one year in 26 (8%) and more than one year in 169 patients (52%). Time since referral was 
unclear in 70 patients (21%). 
The outcomes of all patients are illustrated in figure 1. 69 patients (21%) died within one 
year of initiation of rifaximin. The 30 day, 90 and 180 day mortality rates were 6%, 11% and 
17% respectively. Median baseline MELD score was higher in the patients who died (17.6, 
IQR 8.7) compared with those who remained alive and had not been transplanted at one 
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year (12.6, IQR 5.6; p<0.001). There were 45 patients (14%) who underwent liver 
transplantation within one year of treatment initiation with rifaximin, with a median 
baseline MELD of 17.4 (IQR 6.4). Rifaximin was discontinued in 31 (10%) patients. In five this 
was because no improvement in clinical condition was observed, whilst in 11 the liver 
function had improved substantially, or HE was considered to have resolved. Two patients 
reported adverse events (nausea in one and not recorded in the other) and five were non-
compliant. There were no reported cases of Clostridium difficile infection. 
Univariate analysis showed that, following the commencement of rifaximin, there were 
significant reductions in the number of hospital admissions and hospital length of stay 
(HLOS) (table 3). Data were incomplete across all study periods, but analysis of available 
paired data showed around a fifty per cent reduction in the HLOS at each time point (53.3%, 
53.2% and 52.7% at three, six and 12 months, respectively). There were complete, paired, 
12 monthly data before and after initiation of rifaximin available for 158 (87%) patients who 
remained alive and had not undergone liver transplantation. In these patients there was a 
significant reduction in the mean number of emergency hospital admissions from 2.1 (SD 
1.96) admissions before rifaximin treatment to 1.6 (SD 2.4) during treatment (p=0.001). The 
mean HLOS per admission reduced from 13.5 (SD 15.9) days before to 8.6 (SD 11.5) days 
during rifaximin treatment (p=0.017). This amounted to an overall reduction in the mean 
annual HLOS from 24.4 (SD 29.7) days per year, to 11.5 (SD 18.6) days per year, following 
commencement of rifaximin (p<0.001). When all available data were annualised and 
patients with incomplete follow-up were censored, there was an estimated 31% reduction 
in HLOS (table 3).  
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Figure 2 illustrates the pattern of admissions and HLOS of the 141 patients with complete 
data covering all study periods. This shows that admissions increased over the year prior to 
commencement of rifaximin, with the greatest number and longest HLOS occurring during 
the three months prior to rifaximin initiation (mean 0.35 admissions and 4.47 days per 
month). During rifaximin treatment, hospital admissions decreased, with a progressive 
reduction in the HLOS throughout the year from 2.14 days per month in the year prior, to 
1.02 days per month (p<0.001) in the year following commencement of rifaximin treatment. 
Estimated inpatient costs, using published NHS reference prices, showed that mean annual 
emergency inpatient admission costs were reduced from £12,522 per year prior to rifaximin 
initiation, to £5,915 per year following rifaximin treatment initiation in the patients with 
paired one year follow-up data, an annual saving of £6,607. Inclusion of the drug cost of one 
year’s treatment with rifaximin (£3,379) resulted in a mean saving of £3,228 per patient per 
year. Using the lower estimates derived from annualised data, admission costs were 
reduced by £4,859 (£15,647 per year before to £10,788 during), a saving of £1,480. 
Disease severity data from patients with a MELD score available at both baseline and at 
three months (70—110 days) after treatment initiation with rifaximin (n=118) were 
compared. There was no change from median MELD score at baseline (14.0, IQR 6.3) to 
three months (13.4, IQR 6.5, p=0.309). Similarly, in patients with MELD data at baseline and 
at one year (274—456 days; n=109) there was no significant change from median MELD at 
baseline (11.6, IQR 4.8) to one year (11.8, IQR 5.4; p=0.150).  
Multivariate analysis was performed using all available data with each patient split into two 
periods (total of 632 periods analysed, 97%). Data were censored at the time of death, 
transplant, discontinuation of rifaximin or loss to follow-up. Rifaximin use was associated 
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with significantly shorter HLOS (Odds Ratio (OR) 0.66, 95% CI 0.56-0.79, p<0.001), as shown 
in figure 3. Alcohol consumption also had a considerable impact on HLOS as shown by 
comparing patients who were not abstinent or who had been abstinent for fewer than 90 
days to patients with a non-alcohol aetiology (OR 1.97, 95% CI 1.55-2.49, p<0.001). Female 
patients were also found to have significantly longer HLOS (OR 1.4, 95% CI 1.16-1.69, 
p<0.001). A separate multivariate analysis was carried out including only patients with data 
covering at least one year (456 time periods, 70%). This showed a more marked effect of 
rifaximin on HLOS (OR 0.41, 95% CI 0.33-0.51, p<0.001). TIPSS was associated with shorter 
HLOS in the one year group (OR 0.66, 95% CI 0.48-0.91) but not in the all data analysis. 
Higher MELD scores were associated with longer HLOS in both analyses but lactulose 
prescription and length of specialist care did not affect HLOS. 
Discussion 
This observational study characterised data from seven large, UK hospitals, representative 
of the spectrum of liver centres from district general hospitals to tertiary and liver 
transplant units. We investigated the impact of treatment with rifaximin on hospital 
resource utilisation in patients with HE on a background of cirrhosis. A before and after 
design was used, effectively allowing patients to be used as their own controls, with 
standardised datasets collected from the seven UK centres. We believed that for a 
progressive disease such as advanced liver disease, this would provide a conservative 
picture of any resulting change, given that we would expect there to be a natural increase in 
resource utilisation, resulting from a progressive deterioration in clinical condition. In 
addition, we carried out multivariate analyses to explore the impact of other factors, as well 
as rifaximin, on emergency admissions. 
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There is good evidence for the efficacy of rifaximin as second-line treatment in HE, in 
particular in combination with lactulose (8). However, there remain reservations about the 
cost-effectiveness of the drug and there has been a reluctance to approve its use in some 
countries (12). Given the high level of resource utilisation associated with HE and, in 
particular, high inpatient costs, we aimed to investigate the impact of rifaximin on this 
specific cost of care. Overall, we found commencement of rifaximin was associated with 
around a 50% reduction in the total HLOS at univariate analysis of paired data at 3, 6 and 12 
months, where admissions data were available for the same duration before and during 
rifaximin treatment. The estimated reduction of HLOS was lower, at 31.1%, when censoring 
for missing data by annualising available data. Similarly, multivariate analysis estimated that 
rifaximin resulted in a 34% reduction in a HLOS from all available data, compared with a 59% 
reduction using data covering at least a one year period. It is likely that the non-linear 
distribution of admissions relative to the commencement of rifaximin means that the 
adjusted data over estimates emergency admissions after rifaximin. 
We considered the impact of a number of potential confounding factors by performing 
multivariate analyses. Alongside rifaximin, alcohol consumption was a strongly significant 
factor associated with overall HLOS. In patients with ARLD, continued alcohol consumption 
(or abstinence for less than 90 days) accounted for around double the HLOS compared with 
patients with non-ARLD. On the other hand, ARLD patients with more than 90 days 
abstinence were not significantly different than non-ARLD patients. It is likely that 
abstinence resulted in reduced emergency admissions through a combination of re-
compensation of liver function and fewer alcohol-related admissions, such as due to alcohol 
withdrawal. TIPSS was associated with reduced HLOS in the analysis of patients with at least 
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one year follow-up, but not in the analysis of all patients. One explanation for this is that 
TIPSS led to a reduction in variceal bleeding-related admissions but initially there was an 
excess of admissions due to HE. The length of time patients had been under the care of a 
liver specialist (gastroenterologist or hepatologist) was also examined to determine if 
patients who had been recently referred had other aspects of their care optimised, 
alongside the commencement of rifaximin. However, we found no difference when 
comparing patients who had been under the care of a specialist for less than three months, 
to those attending a specialist for a longer time period.   
Liver disease severity, as measured by MELD score, was found to be significantly associated 
with HLOS, with patients with more severe liver disease admitted more frequently, as would 
be expected. In addition, there was no change from baseline MELD to MELD after either 
three months’ or one year’s treatment with rifaximin.  
To our knowledge there is one other published study which considered the impact of 
rifaximin on healthcare resource utilisation (20). However, this had a number of limitations; 
all patients had been taking lactulose for six months or more for HE and were then switched 
to rifaximin, when the drug became available in the United States. The cohort studied did 
not therefore accurately reflect what is now standard clinical practice, where rifaximin is 
reserved for patients with recurrent overt HE and where it will be prescribed in addition to, 
not instead of, lactulose (7). 
By contrast, our study included patients who were representative of current evidence-based 
practice. The majority (87%) of patients were prescribed concurrent lactulose, similar to the 
91% in the previous RCT (8), and standard practice across all seven centres was for rifaximin 
to be used as a second line therapy. A further strength of our study was the inclusion of 
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seven specialist liver centres (two liver transplant centres, three tertiary liver centres and 
two large district general hospitals). Hence, the results should be generalisable across a 
wide spectrum of clinical practice.  
One potential criticism of our study design could be that all emergency admissions were 
included, rather than only those relating to HE related admissions. We chose this approach 
because pilot work had demonstrated that patients admitted for other, ostensibly unrelated 
reasons (e.g. limb fracture) were found, following case-note review, to have HE as a likely 
contributing factor There is also the possibility that rifaximin has additional beneficial effects 
beyond control of HE, for example in reduction of portal hypertension (21) or in prevention 
of spontaneous bacterial peritonitis (22), therefore inclusion of all emergency admissions 
was considered appropriate. Moreover, HE was not a diagnostic code within the ICD-10 
classification (the coding system used in all NHS hospitals) meaning that HE-related 
admissions were likely to be underestimated. By excluding elective admissions, frequent 
events such as hospital admissions for uncomplicated, large volume paracentesis did not 
contribute. We recognised that some, non-HE related emergency admissions may have 
been included, but this was thought to be constant both before and during rifaximin 
exposure. We have not included other direct healthcare costs, such as primary care 
consultations or emergency department attendances nor are any indirect costs included. 
However, emergency admissions are likely to be the main driver contributing to the high 
costs associated with HE. One other limitation is that there were some missing data, 
particularly in situations where admission data could not be accurately collected because 
patients were admitted to other hospital. In spite of this, our dataset was relatively 
complete, within the limitations of the study design.  
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In conclusion, this study characterised real world data from seven UK specialist liver centres 
and demonstrated that treatment with rifaximin to reduce the frequency of overt HE in 
patients with advanced liver disease was associated with a large reduction in hospital 
admissions and a reduction in length of stay, even when hospital admission was required. 
Before rifaximin treatment, mean annual HLOS was high, consistent with previous reports of 
healthcare resource utilisation (14, 23, 24). Following commencement of rifaximin 
treatment, HLOS was reduced by between 31% and 53%, resulting in a mean saving of 
£4,858- £6,607 per patient per year in hospital admission costs in our cohort. After 
accounting for drug acquisition costs there remained a substantial financial saving of 
between £1,500 and £3,000 per patient per year. 
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Table 1 | Cost estimates: sources and values 
Cost Source Value 
Rifaximin drug cost British National Formulary 
August 2015 (19) 
56 x 550 mg tablets = 
£259.23 
1 year treatment of 550mg 
twice daily = £3,379.25 
Cost of emergency admission 
with liver disease 
NHS reference costs 2013 to 
2014 (18) 
Liver Failure Disorders 
without Interventions, with 
CC Score 0-4: Non-elective 
inpatients short-stay 
Unit cost £513/day  
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Table 2 | Baseline characteristics of included patients 
 
Royal Bolton 
Hospital 
Bristol Royal 
Infirmary 
Ninewells 
Hospital, 
Dundee 
The Royal 
Liverpool 
Hospital 
King’s 
College 
London 
Freeman 
Hospital, 
Newcastle 
Queen 
Alexandra 
Hospital, 
Portsmouth All centres 
Patients (n) 30 45 25 49 78 64 35 326 
Age (years) 60.5 (11.2) 59.8 (12.3) 57.7 (13.1) 55.3 (13.1) 56.9 (12.1) 61.4 (9.5) 58.3 (11.4) 58.5 (11.8) 
Males (n, %) 18 (60.0%) 31 (68.8%) 17 (68.0%) 38 (77.5%) 55 (70.5%) 46 (71.9%) 20 (57.1%) 225 (69.0%) 
TIPSS (n, %) 0 (0.0%) 4 (8.9%) 9 (36.0%) 1 (2.0%) 10 (12.8%) 6 (9.4%) 5 (14.3%) 35 (10.7%) 
Concurrent 
lactulose 
30 (100.0%) 40 (88.9%) 25 (100.0%) 49 (100.0%) 55 (70.5%) 53 (82.8%) 29 (82.9%) 
281 (86.2%) 
Aetiology*        
     ARLD 25 (83.3%) 29 (64.4%) 13 (52.0%) 29 (59.2%) 42 (53.8%) 39 (60.9%) 22 (62.9%) 199 (61.0%) 
    NASH 3 (10.0%) 7 (15.6%) 9 (36.0%) 5 (10.2%) 7 (9.0%) 12 (18.8%) 6 (17.1%) 49 (15.0%) 
    HBV 0 (0.0%) 1 (2.2%) 0 (0.0%) 1 (2.0%) 1 (1.3%) 1 (1.6%) 0 (0.0%) 4 (1.2%) 
    HCV 3 (10.0%) 4 (8.9%) 3 (12.0) 11 (22.4%) 10 (12.8%) 8 (12.5%) 4 (11.4%) 43 (13.2%) 
    
AIH/PBC/PSC 
0 (0.0%) 3 (6.7%) 1 (4.0%) 3 (6.1%) 10 (12.8%) 1 (1.6%) 4 (11.4%) 
22 (6.7%) 
    Cryptogenic 0 (0.0%) 1 (2.2%) 0 (0.0%) 3 (6.1%) 4 (5.1%) 4 (6.3%) 0 (0.0%) 12 (3.7%) 
    
Miscellaneous 
0 (0.0%) 1 (2.2%) 2 (8.0%) 2 (4.1%) 9 (11.5%) 2 (3.1%) 1 (2.9%) 
17 (5.2%) 
Baseline 
MELD: mean 
(SD) 
17.5 (5.6) 14.3 (4.6) 15.3 (5.2) 12.8 (4.6) 16.6 (6.9) 12.9 (3.7) 17.9 (6.9) 
15.1 (5.8) 
    ≤10 1 (3.3%) 10 (22.2%) 3 (12.0%) 13 (26.5%) 8 (10.3%) 10 (15.6%) 4 (11.4%) 49 (15.0%) 
    10-15 11 (36.7%) 18 (40.0%) 9 (36.0%) 21 (42.9%) 32 (41.0%) 36 (56.3%) 12 (34.3%) 139 (42.6%) 
    15-25 15 (50.0%) 15 (33.3%) 11 (44.0%) 15 (30.6%) 26 (33.3%) 17 (26.6%) 15 (42.9%) 114 (35.0%) 
    ≥25 3 (10.0%) 0 (0.0%) 1 (4.0%) 0 (0.0%) 11 (14.1%) 0 (0.0%) 4 (11.4%) 19 (5.8%) 
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    Unknown 0 (0.0%) 2 (4.4%) 1 (4.0%) 0 (0.0%) 1 (1.3%) 1 (1.6%) 0 (0.0% 5 (1.5%)  
Baseline Child 
Pugh class 
       
     A 0 (0.0%) 1 (2.2%) 2 (8.0%) 9 (18.4%) 5 (6.4%) 9 (14.1%) 3 (8.6%) 29 (8.9%) 
    B 12 (40.0%) 16 (35.6%) 14 (56.0%) 24 (49.0%) 39 (50.0%) 37 (57.8%) 11 (31.4%) 153 (46.9%) 
    C 18 (60.0%) 26 (57.8%) 9 (36.0%) 16 (32.7%) 34 (43.6%) 18 (28.1%) 21 (60.0%) 142 (43.5%) 
    Unknown 0 (0.0%) 2 (4.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.6%) 
*Some patients had more than one liver disease aetiology.
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Table 3 | Univariate analysis of admission number and HLOS before and during rifaximin. 
Mean (SD) number of admissions and HLOS (days) is shown where paired (pre- and post-
rifaximin) data was available. Annualised data includes all patients with available admission 
data, with patients who died, were transplanted or discontinued rifaximin censored at the 
time of the event. 
  Before  
rifaximin 
During  
rifaximin Δ p 
3 months 
n=227 (69.6%) 
Admissions 1.17 (1.15) 0.64 (0.96) 45.3% <0.001 
HLOS 15.84 (22.46) 7.40 (14.66) 53.3% <0.001 
6 months 
n=189 (60.0%) 
Admissions 1.62 (1.48) 1.02 (1.47) 37.0% <0.001 
HLOS 20.66 (25.46) 9.66 (16.59) 53.2% <0.001 
12 months 
n=158 (48.5%) 
Admissions 2.11 (1.96) 1.56 (2.39) 26.1% 0.001 
HLOS 24.40 (29.69) 11.53 (18.60) 52.7% <0.001 
All data  
annualised  
n=315 (96.6%) 
Admissions 3.12 (9.77) 1.98 (4.52) 36.5% 0.042 
HLOS 30.50 (21.03) 21.03 (54.18) 31.0% 0.006 
 
Figure Legends 
Figure 1 | Outcomes at one-year post initiation of treatment with rifaximin-α 
Figure 2 | Pattern of mean number of admissions (A) and mean length of emergency 
hospital admissions (B) during study period 
Figure 3 | Multiple regression analysis: negative binomial regression analyses were carried 
out to assess the relative impacts of various factors on HLOS. The following factors were 
included: rifaximin status (rifaximin vs no rifaximin), age, MELD, lactulose status (lactulose vs 
no lactulose), TIPSS (TIPSS vs no TIPSS), specialist care duration (specialist care ≥90days vs 
specialist care <90days), gender (female vs male), alcohol status (1. abstinent ≥90 days, 2. 
not abstinent or abstinent <90days, 3. unknown abstinence status; all vs non-alcohol 
aetiology). Two records were included for each patient: before and after the 
commencement of rifaximin. Patients who died, were transplanted, discontinued rifaximin 
or were lost to follow-up were included and data censored at the time of the event (top 
panel). Patients with a minimum of one year follow-up were also analysed separately 
(bottom panel).  
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